• Profile
Close

Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: The JADE TEEN randomized clinical trial

JAMA Aug 23, 2021

Eichenfield LF, Flohr C, Sidbury R, et al. - According to this multicenter, international, phase 3, randomized, placebo-controlled, parallel-group study (JADE TEEN), oral abrocitinib plus topical therapy was found to be considerably more efficacious than placebo plus topical therapy in adolescents with moderate-to-severe atopic dermatitis (AD), with an acceptable safety profile.

  • There were 285 adolescents with moderate-to-severe AD in this study (145 boys [50.9%] and 140 girls [49.1%]]), 160 (56.1%) of whom were White and 94 (33.0%) of whom were Asian; the median age was 15 years (interquartile range 13-17 years).

  • At week 12, significantly more patients treated with abrocitinib (200 mg or 100 mg) compared with placebo had an IGA response of 0/1, 75% or greater improvement from baseline in Eczema Area and Severity Index, and 4 points or more in Peak Pruritus Numerical Rating Scale.

  • In the 200 mg, 100 mg, and placebo groups, adverse events were recorded by 59 (62.8%), 54 (56.8%), and 50 (52.1%) patients, respectively; nausea was more common with abrocitinib, 200 mg (17 [18.1%]) and 100 mg (7 [7.4%]).

  • Herpes-related AEs were uncommon; only 1 (1.1%), 0 (0%), and 2 (2.1%) patients suffered serious AEs.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay